In the first quarter of 2022, AstraZeneca posted record revenues of $11.39 billion, representing a remarkable 56% increase year-over-year, significantly beating analyst forecasts. The company's core operating profit reached $3.96 billion, but it faces challenges as it anticipates a substantial decline in sales from COVID-19 products, projecting a drop of 20% this year. Additionally, AstraZeneca is set to enhance its R&D footprint with a new center in Cambridge, Massachusetts, following its $39 billion acquisition of Alexion Pharmaceuticals.
“FDA · granted priority review to · AstraZeneca’s BLA for tremelimumab · true”
“AstraZeneca · announced · FDA granted priority review · for tremelimumab”
“AstraZeneca · filed · supplemental BLA for Imfinzi · yes”
“AstraZeneca PLC · plans to open · a research-and-development center · in a new Boston Properties Inc. building in Cambridge’s Kendall Square”
“AstraZeneca PLC · will move · Alexion Pharmaceuticals’ headquarters · to the site from the Seaport District”
“AstraZeneca PLC · will move · about 1,500 employees · to a facility to be built at 290 Binney St.”
“AstraZeneca · acquired · Boston-based Alexion · last year in a blockbuster $39 billion deal”
“AstraZeneca · first-quarter 2022 core earnings · 95 cents per American depositary share (ADS) · beat the Zacks Consensus Estimate of 85 cents”
“AstraZeneca · core earnings · $1.89 per share · rose 16% year over year on a reported basis and 20% at constant exchange rates (CER)”
“AstraZeneca · total revenues · $11.39 billion · were up 56% on a reported basis and 60% at CER”
“AstraZeneca · total revenues · $11.39 billion · beat the Zacks Consensus Estimate of $11.14 billion”
“AstraZeneca’s core gross margin · was · 79.3% · up 4 percentage points at CER”
